| |
| |
|
| Insider
Information: |
Fust Matthew K |
| Relationship: |
Director |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
351,844 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$8,143,493 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
351,844 |
|
|
| Total
Value |
$8,143,493 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -16.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Jazz Pharmaceuticals Inc |
JAZZ |
EVP, Chief Financial O... |
2008-11-28 |
58,948 |
|
0 |
Premium* |
|
|
Onyx Pharmaceuticals Inc |
ONXX |
EVP & Chief Financial ... |
2013-10-01 |
0 |
2009-01-05 |
0 |
Premium* |
|
|
Ultragenyx Pharmaceutical Inc |
RARE |
|
2024-03-07 |
14,860 |
2014-01-30 |
0 |
Premium* |
|
|
Macrogenics Inc |
MGNX |
Director |
2019-02-06 |
500 |
|
0 |
Premium* |
|
|
Atara Biotherapeutics, Inc. |
ATRA |
|
2024-03-31 |
259,000 |
2015-05-15 |
0 |
Premium* |
|
|
Crinetics Pharmaceuticals, Inc. |
CRNX |
Director |
2024-03-20 |
18,536 |
2019-12-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
96 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2017-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
15,069 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2017-08-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,603 |
28,901 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2017-11-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,602 |
30,503 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2018-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,603 |
32,106 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2018-05-14 |
4 |
S |
$43.57 |
$535,301 |
D/D |
(12,286) |
19,820 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2018-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
534 |
20,354 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2018-05-30 |
4 |
AS |
$72.00 |
$454,969 |
D/D |
(6,319) |
8,750 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
21,854 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2018-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
11,750 |
0 |
- |
|
| MGNX |
Macrogenics Inc |
Director |
– • – |
2019-02-06 |
4 |
OE |
$20.15 |
$139,519 |
D/D |
6,924 |
7,424 |
0 |
- |
|
| MGNX |
Macrogenics Inc |
Director |
– • – |
2019-02-06 |
4 |
AS |
$29.38 |
$203,427 |
D/D |
(6,924) |
500 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2019-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
14,750 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2019-06-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
25,854 |
0 |
- |
|
| CRNX |
Crinetics Pharmaceuticals... |
Director |
– • – |
2019-12-16 |
4 |
OE |
$1.91 |
$6,685 |
D/D |
3,500 |
16,036 |
0 |
- |
|
| CRNX |
Crinetics Pharmaceuticals... |
Director |
– • – |
2019-12-16 |
4 |
AS |
$22.50 |
$78,750 |
D/D |
(3,500) |
12,536 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2020-04-22 |
4 |
AS |
$65.00 |
$121,875 |
D/D |
(1,875) |
12,875 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2020-05-18 |
4 |
AS |
$75.00 |
$140,625 |
D/D |
(1,875) |
11,000 |
0 |
% |
|
| ATRA |
Atara Biotherapeutics, In... |
Director |
– • – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
33,854 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2020-07-01 |
4 |
OE |
$21.00 |
$105,000 |
D/D |
5,000 |
18,550 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2020-07-01 |
4 |
AS |
$85.00 |
$425,000 |
D/D |
(5,000) |
13,550 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2020-07-06 |
4 |
AS |
$90.00 |
$556,290 |
D/D |
(6,181) |
13,550 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2020-07-06 |
4 |
OE |
$21.00 |
$129,801 |
D/D |
6,181 |
19,731 |
0 |
- |
|
| ATRA |
Atara Biotherapeutics, In... |
|
• • – |
2021-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
44,854 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
Director |
– • – |
2021-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,145 |
15,695 |
0 |
- |
|
| CRNX |
Crinetics Pharmaceuticals... |
Director |
– • – |
2021-07-12 |
4 |
OE |
$1.91 |
$9,550 |
D/D |
5,000 |
17,536 |
0 |
- |
|
96 Records found
|
|
Page 3 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
